Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim to launch phase III trial of leukaemia drug

Boehringer Ingelheim to launch phase III trial of leukaemia drug

11th December 2012

Boehringer Ingelheim has announced plans to initiate a phase III clinical trial of a potential new therapy for leukaemia.

The company will commence a trial in early 2013 that will assess the investigational haematology/oncology compound volasertib in newly diagnosed patients with acute myeloid leukaemia considered ineligible for intensive remission induction therapy.

In an earlier phase II study, the compound demonstrated the potential survival benefits it can provide when administered in combination with low-dose cytarabine.

The planned phase III trial will be called Polo-AML-2 and will begin to enrol eligible patients aged 65 or older next year.

Professor Klaus Dugi, corporate senior vice-president for medicine at Boehringer Ingelheim, said: "Based on the results observed in this difficult-to-treat patient population, we are expanding our volasertib haematology clinical programme to further explore this investigational compound."

Last month, the company completed enrolment for a clinical trial assessing cardiovascular outcomes associated with its Trajenta diabetes therapy.ADNFCR-8000103-ID-801504292-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips and straight to your inbox.